 This is a Phase 1 first-in-human, non-randomized individuals will not be assigned by chance to study treatments, open-label individuals will know the identity of study treatments, multicenter, 2-part, dose-escalation study to evaluate the safety, pharmacokinetics study of what the body does to a drug of E7389 LF administered orally to patients with solid tumors. Each treatment cycle will be 21 days Schedule 1 or 28 days Schedule 1a or 2. Part 1 is the dose-escalation phase, which will be guided by pharmacokinetics and safety. Three to 6 new patients will be enrolled in sequential cohorts first cohort will receive the starting dose and subsequent cohorts will receive increased doses of E7389 LF. Enrollment in each cohort will be staggered; the second and third participant in every cohort will not be dosed until the first patient in that cohort completes 2 weeks of Cycle 1. If no dose-limiting toxicities DLTs have been observed during the first 2 week of Cycle 1 in the first patient, the second and third patients in the cohort will initiate treatment. Enrollment will be first initiated into cohort 1 of Schedule 1 dosing on Day 1 of 21 day cycle. Interim analysis will be conducted upon completion of this cohort. The following decisions will be made based upon the results of the interim analysis 1 proceed with escalating to next dose level cohort 2 of Schedule 1 dosing on Day 1 of 21 day cycle and initiate cohort 1 of Schedule 2 dosing on Day 1 and Day 15 of 28 day cycle, or 2 discontinue plans to evaluate Schedule 2 and initiate Schedule 1a dosing on Day 1 of 28 day cycle. 